Result description
We have outlined the technology, which énables automated and asynchronous extraction of cfDNA from whole blood. This technology can sort out the logistical problems in the liquid biopsy studies and labor-intensive sample handling (two-times centrifugation), offering a valuable tool for safe and reliable prenalaytical processing of blood samples.
Addressing target audiences and expressing needs
- Venture Capital
Looking for VC’s understanding the potential of liquid biopsy markets and preanalytical health technologies.
- Research and Technology Organisations
- Private Investors
R&D, Technology and Innovation aspects
Technology has been experimentally tested in laboratory (TRL3) in two separate steps. We are currently combining the steps and designing a prototype for 3D printing/milling. The product will be validated and demonstrated in relevant environment by summer 2021. Aftyer the project, established company has been successfully taken part in the corona diagnostics, which has decreased the need of external investor funding.

